This page shows the latest HTA news and features for those working in and with pharma, biotech and healthcare.
diagnostics. The health technology assessment (HTA) agency launched a public consultation last week on a proposal for changes to the methods it uses to evaluate potential medical treatments. ... The HTA agency has already identified potential areas for
health technology assessment (HTA) policies and processes.
NICE has become one of the world’s most prominent and well-know health technology assessment (HTA) bodies since its inception in 1999. ... NICE International will build on the expertise of those within the organisation and draw on links with academic
NICE quickly became the world’s best-known and most prominent health technology assessment (HTA) body, and has set the standard for many other national institutes set up since then.
2019 has already been very eventful in terms of the debate about pharma’s future, including the question of how to proceed with plans for harmonisation of health technology assessment (HTA)
Resistance to high prices, even with novel payment models. Europe’s leading nations should commit to a rapid overhaul of health technology assessment (HTA) and bold initiatives such as new ... Better-adapted health technology assessment (HTA) methods,
More from news
Approximately 32 fully matching, plus 150 partially matching documents found.
Establishing value, of course, necessitates assessment – whether that’s through a health technology assessment (HTA) style procedure or something else.
The access landscape is further complicated because many health technology assessment (HTA) methodologies are currently not geared up to evaluate these treatments. ... Yet NICE and many other HTA bodies limit their assessment to the cost-effectiveness of
This involves working with HTAs to evolve treatment assessment to be more meaningful for everyone and crucially to be more holistic and less siloed.
Similarly, commercial teams need to drill down and understand HTA requirements within the disease category to ensure trials are designed to capture the necessary data for modelling. ... When drugs don’t receive HTA regulatory support in major markets,
preferences data could be used in HTA.
More from intelligence
Approximately 14 fully matching, plus 62 partially matching documents found.
value dossiers, payer-focused objection handlers, stand-alone payer value propositions and local HTA submissions.
He becomes its new HTA director. AstraZeneca’s former global price and reimbursement director Claes Buxfeldt has joined the NDA advisory board. ... Buxfeldt’s new role at NDA will see him drive and develop the group’s service offerings in the HTA
She most recently spent the 18 years at the National Institute for Health and Care Excellence ( NICE), where she has led the HTA organisation’s technology appraisal programme.
her focus on expanding the company’s market access capabilities, spanning payer strategy, health economics and outcomes research (HEOR), health technology assessment (HTA) and communications support.
At the ABPI Torbett will focus on pricing, the Pharmaceutical Price Regulation Scheme (PPRS), health technology assessments (HTA) and value assessment, as well as market access in the UK.
More from appointments
Approximately 0 fully matching, plus 7 partially matching documents found.
But the UK also needs an HTA system fit for the future. ... From the Cancer Drugs Fund to the promised Innovation Drugs Fund, initiatives have been created as technical ‘work-arounds’ for NICE and for an HTA system that has not kept pace
OPEN Health introduce an overview of regulatory and HTA developments for digital therapeutics in Europe focusing on Germany and the UK.
Hence, similar to other markets, successful market access in France necessitates a thorough understanding of Health Technology Assessment (HTA) hurdles and the competitive landscape early in the product development, thorough market ... 9833. References.
Market access strategies have evolved over the years. Initially, the goal was to gain a positive recommendation from health technology assessment (HTA) submissions. ... The expectations from an expert-led market access strategy is no longer limited to
This round table brings together leading experts from the pharmaceutical industry, HTA bodies and public health experts to discuss consequences, threats and opportunities, and how to maintain continuity. ... Ex-member of the Italian Government Drug
More from PMHub
Approximately 6 fully matching, plus 22 partially matching documents found.
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...